Loading market movers...

DT120

Phase 3

Definium Therapeutics, Inc. (DFTX)

00%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Sep '27

DFTXPhase 3$5.1B

DT120 Phase 3 Est. Readout

DT120• Major Depressive Disorder165

Sep 2027~Estimated

00%

Competitive Landscape

13 competitors in Major Depressive Disorder

ITCILumateperone

AXSMAXS-05 (dextromethorphan and bupropion) oral tablets

XENEAzetukalner

View Full Landscape

Drug Information

Target Indication

Major Depressive Disorder

Clinical Trial

Last updated: 5/19/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

DFTX

Definium Therapeutics, Inc.

Medicinal Chemicals & Botanical Products•North America•NASDAQ

Related Pipeline

MM120 (LSD D-Tartrate)Phase 3

Generalized Anxiety Disorder

MM-120 (LSD D-Tartrate)Phase 2

Anxiety Generalized

ADHD

MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))Phase 2

Autism Spectrum Disorder

DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))Phase 2

Autism Spectrum Disorder

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts